Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CA209-8Y8 trial: what clinicians have said so far
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
- NCT03873402 ↗
- Active, not recruiting
- Bristol-Myers Squibb
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on CA209-8Y8 (previously untreated intermediate/poor-risk advanced renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CA209-8Y8 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy for Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Renal Cell Carcinoma
- Interventions
- Nivolumab; Ipilimumab; Ipilimumab placebo
- Arms
- Nivolumab + ipilimumab · Experimental
- Nivolumab + ipilimumab placebo · Experimental
- Enrollment
- 437
- Primary outcomes
- Progression free survival (PFS) by blinded independent central review (BICR)
- Objective response rate (ORR) by BICR
- Sponsor
- Bristol-Myers Squibb
- Start
- Jun 21, 2019
- Primary completion
- Mar 11, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03873402 · updated Jan 21, 2026